文献速递银屑病与炎症性皮肤病

银屑病患者血液炎症与心血管蛋白在托法替布和依那西普治疗4周后的差异降低

Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PubMed 文献 · J Invest Dermatol · 2017-09-18

本研究基于一项中重度银屑病3期临床试验的存档血样,用邻位延伸分析法定量266例患者基线和第4周的157种血液蛋白,比较托法替布(10 mg 每日两次)与依那西普(50 mg 每两周一次)治疗1个月后的蛋白变化,并按第12周应答状态分析。结果显示两药共同降低IL-6、CCL20和CXCL10,IL-17A仅在应答者中显著降低;托法替布降低心血管蛋白的谱更广,但严格限于治疗应答者。

要点

  • 托法替布与依那西普均降低IL-6、CCL20和CXCL10,IL-17A仅在应答者中显著降低。
  • 托法替布降低心血管相关血液蛋白的谱比依那西普更广,但效应仅见于治疗应答者。
  • 短期系统治疗即可降低循环中与心血管风险相关的炎症及其他蛋白。

核心结论

  • 短期系统治疗银屑病可降低循环中与心血管风险相关的炎症及其他蛋白。
  • 托法替布降低心血管蛋白的谱比依那西普更广,但严格限于治疗应答者。

研究设计与样本

  • 研究基于托法替布与依那西普治疗中重度银屑病3期临床试验的存档血样。
  • 用邻位延伸分析法定量266例患者基线和第4周的157种血液蛋白。
  • 比较托法替布10 mg每日两次与依那西普50 mg每两周一次治疗1个月后的蛋白变化,并按第12周应答状态分析。

主要发现

  • 托法替布和依那西普共同降低IL-6、CCL20和CXCL10。
  • IL-17A仅在任一治疗的应答者中显著降低。
  • 与依那西普相比,托法替布显示更广的心血管血液蛋白降低谱。
  • 托法替布的蛋白降低效应严格限于治疗应答者。
  • TNF受体1、E-选择素、hK11、TNF相关激活诱导细胞因子、CHI3L1、IL-16和MMP-12仅在托法替布应答者中显著降低。

关键数值与推荐

  • 托法替布剂量为10 mg每日两次,依那西普为50 mg每两周一次。
  • 共分析266例患者基线和第4周的157种血液蛋白。
  • 应答状态按第12周评估。

临床怎么用

  • 银屑病系统治疗可能短期改善与心血管风险相关的循环蛋白。
  • 托法替布对心血管蛋白的降低效应仅见于治疗应答者,需关注应答状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with psoriasis have an increased risk of myocardial infarction, and psoriasis is now recognized as an independent risk factor for coronary heart disease and cardiovascular mortality. To understand the effects of psoriasis medications on systemic inflammation associated with cardiovascular risks, we studied blood proteins related to inflammation and cardiovascular disease archived from a phase 3 clinical trial of tofacitinib and etanercept in adults with moderate-to-severe psoriasis. A total of 157 blood proteins were quantified by a proximity extension assay from 266 patients at baseline and week 4. Protein changes in the blood after 1 month of treatment were compared between tofacitinib (10 mg two times a day) and etanercept (50 mg biweekly), and by response status at week 12. Tofacitinib and etanercept commonly reduced IL-6, CCL20, and CXCL10, but IL-17A was significantly reduced only in responders of either treatment. Compared with etanercept, tofacitinib showed a wider spectrum of cardiovascular blood protein reduction, but the protein reduction effects of tofacitinib were strictly confined to treatment responders. Tumor necrosis factor receptor 1, E-selectin, hK11, tumor necrosis factor-related activation-induced cytokine, CHI3L1, IL-16, and matrix metalloproteinase-12 were cardiovascular proteins significantly reduced only in tofacitinib responders. Our data suggest that a short-term systemic psoriasis treatment can cause reductions in circulating inflammatory and other proteins associated with cardiovascular risks.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Kim J, Tomalin L, Lee J, et al. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. J Invest Dermatol. 2017. PMID: 28927890. doi:10.1016/j.jid.2017.08.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。